Chu Cheng-Feng, Mao Shih-Hsuan, Shyu Victor Bong-Hang, Chen Chih-Hao, Chen Chien-Tzung
Department of Plastic and Reconstructive Surgery, Keelung Chang Gung Memorial Hospital, Keelung 204, Taiwan.
Department of Plastic and Reconstructive Surgery, College of Medicine, Chang Gung University, Linkou Chang Gung Memorial Hospital, Craniofacial Research Center, Taoyuan 333, Taiwan.
J Pers Med. 2021 Dec 7;11(12):1326. doi: 10.3390/jpm11121326.
Allogeneic bone-marrow mesenchymal stem cells (BMSCs) can promote bone regeneration and substitute for autologous BMSCs if autologous sources are unavailable, but the efficacy of bone regeneration by allogeneic BMSCs is still inconsistent. A Lewis rat cranium defect model was used to investigate the efficacy of bone regeneration between autologous and allogeneic BMSCs in gelatin-nanohydroxyapatite cryogel scaffolds. BMSCs from Wistar rats served as the allogeneic cell lineage. The full-thickness cranium defects were treated by either blank control, cryogel only, allogeneic BMSC-seeded cryogel, or autologous BMSC-seeded cryogel ( = 5). Bone regeneration was monitored by micro-computed tomography and examined histologically at week 12. In addition, we assessed the immune responses in vitro by mixed lymphocyte reaction (MLR) assay and CD immunochemistry staining ex vivo. The MLR showed that allogeneic BSMCs elicited a weak immune response on day 14 that progressively attenuated by day 28. In vivo, the bone regeneration in allogeneic BMSCs was inferior at week 4, but progressively matched the autologous BMSCs by week 12. Our results suggest that allogeneic BMSCs can serve as an alternative source for bone regeneration.
异基因骨髓间充质干细胞（BMSCs）可促进骨再生，并且在无法获得自体来源时可替代自体BMSCs，但异基因BMSCs的骨再生疗效仍不一致。使用Lewis大鼠颅骨缺损模型研究自体和异基因BMSCs在明胶-纳米羟基磷灰石冷冻凝胶支架中的骨再生疗效。来自Wistar大鼠的BMSCs作为异基因细胞系。全层颅骨缺损分别采用空白对照、仅冷冻凝胶、接种异基因BMSCs的冷冻凝胶或接种自体BMSCs的冷冻凝胶进行治疗（每组n = 5）。通过微型计算机断层扫描监测骨再生，并在第12周进行组织学检查。此外，我们通过混合淋巴细胞反应（MLR）试验在体外评估免疫反应，并在体内通过CD免疫化学染色进行评估。MLR显示，异基因BMSCs在第14天引起微弱的免疫反应，并在第28天逐渐减弱。在体内，异基因BMSCs在第4周时骨再生较差，但到第12周时逐渐与自体BMSCs相当。我们的结果表明，异基因BMSCs可作为骨再生的替代来源。
